PROSPECTS FOR THE PREVENTION OF HPV-ASSOCIATED CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Human papillomavirus (HPV) is an extensive group of viruses, some of which have a proven carcinogenic activity. In the absence of specific treatment for HPV, the only effective way to prevent cervical cancer (CC) and other dangerous HPV-associated diseases is to prevent HPV infection. For this purpose, three HPV vaccines, such as bivalent, quadrivalent, and nonavalent ones, have been currently registered and are actively used in the world. HPV vaccines have been included in the national immunization programs of 86 countries (for example, over 10 years in Australia, the incidence of CIN2+ anogenital warts has decreased by more than 2 times and by more than 90%, respectively).

Full Text

Restricted Access

About the authors

Kirill I. Gusakov

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology

Email: kigusakov@gmail.com
MD, pre-PhD 117997

Niso Mirzoevna Nazarova

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology

Email: grab2@yandex.ru
MD, Senior Research Fellow 117997

Vera Nikolaevna Prilepskaya

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology

Email: vprilepskaya@mail.ru
MD, Professor, Deputy Director for Science 117997

Nataliia Leonidovna Starodubtseva

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology

Email: n_starodubtseva@oparina4.ru
PhD, Head of Laboratory of Proteomics of Human Reproduction 117997

Vladimir Evgenievich Frankevich

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology

Email: v_frankevich@oparina4.ru
PhD, Head of Department of Systems Biology in Reproduction 117997

References

  1. WHO. IARC Monographs on the evaluation of carcinogenic risks to humans. IARC Monographs, Volume 10(B). 2012.
  2. Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., Ball L.A., eds. Virus taxonomy: 8th ICTV report of the international committee on taxonomy. Elsevier, Academic Press; 2005. 1259 p.
  3. Castellsague X, de Sanjose S, Aguado K. et al. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine. 2007; 25(Suppl. 3): C1-230.
  4. Egawa K. Do human papillomaviruses target epidermal stem cells? Dermatology. 2003; 207(3): 251-4.
  5. Herfs M, Vargas S.O., Yamamoto Y., Howitt B.E., Nucci M.R., Hornick J.L. et al. A novel blueprint for “top down” differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J. Pathol. 2013; 229(3): 460-8.
  6. Herfs M., Yamamoto Y, Laury A., Wang X., Nucci M.R., McLaughlin-Drubin M.E. et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl. Acad. Sci. USA. 2012; 109(26): 10516-21.
  7. Potten C.S. Cell replacement in epidermis (keratopoiesis) via discrete units of proliferation. Int. Rev. Cytol. 1981; 69: 271-318.
  8. Schmitt A., Rochat A., Zeltner R., Borenstein L., Barrandon Y., Wettstein F.O., Iftner T. The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J. Virol. 1996; 70: 1912-22.
  9. Steben M., Tan Thompson M., Rodier C. Review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J. Obstet. Gynaecol. Can. 2018; 40(12): 1635-45.
  10. Мальцева Л.И., Ахметзянова А.В., Фаррахова Л.Н., Нигматуллина Н.А. Цервикальная интраэпителиальная неоплазия: возможности диагностики и лечения. Практическая медицина. 2012, 9: 52-5.
  11. Bruni L. et al. IARC/ICO Information Centre on HPV and Cancer (HPV Information Centre. Human papillomavirus and related diseases in Russian Federation. Summary Report 10 December 2018. Availadle at: http://www. hpvcentre.net/statistics/reports/RUS.pdf?t=1548009998402
  12. Грецова О.П., Костин А.А., Самсонов Ю.В., Петрова Г.В., Простое М.Ю., Простое Ю.И. Заболеваемость и смертность от злокачественных новообразований, ассоциированных с вирусом папилломы человека. Исследования и практика в медицине. 2017; 4(3): 33-50.
  13. Greer C.E., Wheeler C.M., Ladner M.B., Beutner K., Coyne M.Y., Liang H. et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J. Clin. Microbiol. 1995; 33(8): 2058-63.
  14. Sturegard E., Johansson H., Ekstrom J., Hasson B.G., Johnsson A., Gustafsson E. et al. Human papillomavirus typing in reporting condyloma. Sex. Transm. Dis. 2013; 40(2): 123-9.
  15. Castellsague X., Cohet C., Puig-Tintore L.M., Acebes L.O., Salinas J., San Martin M. et al. Epidemiology and cost of treatment of genital warts in Spain. Eur. J. Public Health. 2009; 19(1): 106-10.
  16. Desai S., Wetten S., Woodhall S.C., Peters L., Hughes G., Soldan K. Genital warts and cost of care in England. Sex. Transm. Infect. 2011; 87(6): 464-8.
  17. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infectious Diseases. 2013; 13: 39.
  18. HPV and Men - Fact Sheet Centers for Disease Control and Prevention DQ, February 4, 2015.
  19. Centers for Disease Control and Prevention (CDC). Human papillomavirus- associated cancers - United States, 2004-2008. MMWR Morb. Mortal. Wkly Rep. 2012; 61: 258-61.
  20. Zhou J. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991; 185(1): 251-7.
  21. Kirnbauer R. Papillomavirus L. major capsid protein self-assembles into viruslike particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 1992; 89(24): 12180-4.
  22. Human Papillomavirus (HPV) Vaccine Merck Sharp & Dohme. July 2018. (Электронный ресурс). Available at: https://www.msdmanuals.com/ professional/infectious-diseases/immunization/human-papillomavirus-hpv-vaccine
  23. Еженедельный эпидемиологический бюллетень. 2014; 43: 89, 465-92. Вакцины против папилломавирусной инфекции человека: документ по позиции ВОЗ, октябрь 2014. (Электронный ресурс). Available at: https:// www.who.int/immunization/policy/position_papers/PP_HPV_Russian_ Oct2014.pdf
  24. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. U.S. Food & Drug Administration; 5 October 2018. (Электронный ресурс). Available at: https://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm622715.htm
  25. Markowitz L.E., Dunne E.F., Saraiya M., Chesson H.W., Curtis C.R., Gee J. et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2014; 63(RR-05): 1-30.
  26. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) “Updated Recommendations on Human Papillomavirus (HPV) vaccine and clarification of minimum intervals between doses in the HPV immunization schedule”. July 2016.
  27. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) “Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised population. May 2017.
  28. Schellenbacher C., Roden R.B., Kirnbauer R. Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res. 2017; 231: 166-75.
  29. Center for Disease Control and Prevention. Recommended Immunizations for Children 7-18 Years Old, 2018. Janaury 17, 2018 CS289048-A. (Электронный ресурс). Available at: https://www.cdc.gov/vaccines/schedules/downloads/ teen/parent-version-schedule-7-18yrs.pdf
  30. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007; 356(19): 1915-27.
  31. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S. et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007; 356(19): 1928-43.
  32. Jour a E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A. et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007; 369(9574): 1693-702.
  33. Lehtinen M., Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017 Aug; 7(8): e015867.
  34. Patel C., Brotherton J.M., Pillsbury A., Jayasinghe S., Donovan B., Macartney K., Marshall H. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018; 23(41).
  35. Korostil I., Ali H., Guy R., Donovan B., Law M.G., Regan D.G. Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males. Sex. Transm. Dis. 2013; 40(11): 833-5.
  36. Белоцерковцева Л.Д., Майер Ю.И., Коваленко Л.В. Репродуктивное поведение подростков и опыт профилактики ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(1): 92-100
  37. Зароченцева Н.В., Белая Ю.М., Джиджихия Л.К. Вакцинопрофилактика рака шейки матки и заболеваний, ассоциированных с вирусом папилломы человека: вопросы и ответы. Российский вестник акушера-гинеколога. 2017; 17(5): 23-8
  38. Esquerre M., Bouillette-Marussig M., Goubier A., Momot M., Gonindard C., Keller H. et al. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. PLoS One. 2017;12(3): e0174038.
  39. Зардиашвили М.Д., Франкевич В.Е., Назарова Н.М., Бугрова А.Е., Кононихин А. С., Бржозовский А.Г., Стародубцева Н.Л., Асатурова А.В., Сухих Г.Т. Характеристика изменений протеомного состава цервиковагинальной жидкости при заболеваниях шейки матки, ассоциированных с ВПЧ-инфекцией. Акушерство и гинекология. 2017; 4: 88-94.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies